CA1027478A - Composition and method for promotion of protein synthesis and suppression of urea formation in the body - Google Patents

Composition and method for promotion of protein synthesis and suppression of urea formation in the body

Info

Publication number
CA1027478A
CA1027478A CA176,339A CA176339A CA1027478A CA 1027478 A CA1027478 A CA 1027478A CA 176339 A CA176339 A CA 176339A CA 1027478 A CA1027478 A CA 1027478A
Authority
CA
Canada
Prior art keywords
promotion
suppression
composition
protein synthesis
urea formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA176,339A
Other languages
English (en)
French (fr)
Other versions
CA176339S (en
Inventor
Mackenzie Walser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1027478A publication Critical patent/CA1027478A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA176,339A 1972-07-13 1973-07-12 Composition and method for promotion of protein synthesis and suppression of urea formation in the body Expired CA1027478A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27098672A 1972-07-12 1972-07-12
US35532773A 1973-04-30 1973-04-30

Publications (1)

Publication Number Publication Date
CA1027478A true CA1027478A (en) 1978-03-07

Family

ID=26954620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA176,339A Expired CA1027478A (en) 1972-07-13 1973-07-12 Composition and method for promotion of protein synthesis and suppression of urea formation in the body

Country Status (5)

Country Link
JP (1) JPS4950121A (enExample)
CA (1) CA1027478A (enExample)
DE (1) DE2335215B2 (enExample)
FR (1) FR2226993A1 (enExample)
IL (1) IL42726A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530246A1 (de) * 1975-07-07 1977-01-13 Fresenius Chem Pharm Ind L-aminosaeuregemische fuer parenterale oder orale anwendung
DE2531299A1 (de) * 1975-07-12 1977-01-13 Fresenius Chem Pharm Ind L-amino- und hydroxy- und/oder ketosaeuren enthaltende gemische fuer parenterale oder orale anwendung
DE2636828A1 (de) * 1976-08-16 1978-02-23 Fresenius Chem Pharm Ind L-amonosaeurengemische fuer die behandlung von leberinsuffizienz sowie die herstellung derartiger gemische
SE7806692L (sv) * 1977-07-01 1979-01-02 Pfizer Anvendning for medicinska endamal av vissa fenylglyoxalsyror, estrar och salter derav
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
SE8803143L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Alternativa energisubstrat
DE3936319C3 (de) * 1989-11-01 1997-05-07 Bartz Volker Phosphatbinder zur oralen Verabreichung
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
DE3943424A1 (de) * 1989-12-30 1991-07-04 Nephro Medica Pharma Infusions- und injektionsloesung zur intravenoesen verabreichung
EP2699112A1 (en) * 2011-04-18 2014-02-26 Nestec S.A. Nutritional compositions having alpha-hica and citrulline

Also Published As

Publication number Publication date
DE2335215B2 (de) 1979-04-05
FR2226993A1 (en) 1974-11-22
IL42726A (en) 1977-10-31
DE2335215A1 (de) 1974-01-31
AU5794173A (en) 1975-01-16
FR2226993B1 (enExample) 1977-07-08
JPS4950121A (enExample) 1974-05-15

Similar Documents

Publication Publication Date Title
CA1022889A (en) Package and method of forming the same
NL7504408A (nl) Materiaal ter bevordering van de eiwitsynthese en voor het handhaven van stikstof in het lichaam.
CA1027478A (en) Composition and method for promotion of protein synthesis and suppression of urea formation in the body
CA1020937A (en) Shaped solid body of pullulan ether and methods of making and using the same
AU477309B2 (en) Improvements in or relating to method of reduction of silicon-dioxide
AU469926B2 (en) Adhesive compositions and method of making plywood
CA1023664A (en) Composition and method for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy-acid analogs of amino acids
CA985674A (en) Cephalosporins useful as intermediates in making cephalexin and improved process for the synthesis of cephalexin
AU468521B2 (en) Improvements in and relating to the application of metal fillings to thermoplastic components
CA963312A (en) Enhancing the flavor of materials intended for human consumption
AU488193B2 (en) Composition and method for promotion or protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy-acid analogs of amino acids
AU488074B2 (en) Composition and method for promotion of protein synthesis and suppression of urea formation inthe body
CA990454A (en) Dry cutting compound for protein glues and method of use
CA1003753A (en) Method and composition for improving hair body and manageability
AU455153B2 (en) New malonyl urea derivatives and process for their preparation
CA897079A (en) Container body and method of making the same
CA927076A (en) Process for the manufacture of fine particulate maddrell's salt
CA952252A (en) Dress and method of dressing
CA914698A (en) Compositions of substituted guanidines and method of use thereof
CA964267A (en) Intermediates in the synthesis of pteridine derivatives and method
CA895815A (en) Sweetening composition and method of producing the same
CA907021A (en) Integrated process for the preparation of urea and melamine
CA809033A (en) Container body and method of making same
CA891831A (en) Flavor-releasing smoking article and method of making the same
CA845075A (en) Sweetened compositions for animal consumption and method of preparing the same